Publications

Export 3785 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E [F] G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
F
Fouda, A. Y., Z. Xu, J. Suwanpradid, M. Rojas, E. shosha, T. Lemtalsi, C. Patel, J. Xing, S. A. Zaidi, W. Zhi, et al., "Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair.", Cell death & disease, vol. 13, issue 8, pp. 745, 2022. Abstract

Current therapies for treatment of proliferative retinopathy focus on retinal neovascularization (RNV) during advanced disease and can trigger adverse side-effects. Here, we have tested a new strategy for limiting neurovascular injury and promoting repair during early-stage disease. We have recently shown that treatment with a stable, pegylated drug form of the ureohydrolase enzyme arginase 1 (A1) provides neuroprotection in acute models of ischemia/reperfusion injury, optic nerve crush, and ischemic stroke. Now, we have determined the effects of this treatment on RNV, vascular repair, and retinal function in the mouse oxygen-induced retinopathy (OIR) model of retinopathy of prematurity (ROP). Our studies in the OIR model show that treatment with pegylated A1 (PEG-A1), inhibits pathological RNV, promotes angiogenic repair, and improves retinal function by a mechanism involving decreased expression of TNF, iNOS, and VEGF and increased expression of FGF2 and A1. We further show that A1 is expressed in myeloid cells and areas of RNV in retinal sections from mice with OIR and human diabetic retinopathy (DR) patients and in blood samples from ROP patients. Moreover, studies using knockout mice with hemizygous deletion of A1 show worsened RNV and retinal injury, supporting the protective role of A1 in limiting the OIR-induced pathology. Collectively, A1 is critically involved in reparative angiogenesis and neuroprotection in OIR. Pegylated A1 may offer a novel therapy for limiting retinal injury and promoting repair during proliferative retinopathy.

Fouda, U. M., M. M. Abou ElKassem, S. M. Hefny, R. M. Fouda, and A. T. Hashem, "Role of fetal echocardiography in the evaluation of structure and function of fetal heart in diabetic pregnancies.", The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, vol. 26, issue 6, pp. 571-5, 2013 Apr. Abstract

OBJECTIVE: To detect the structural and functional changes of fetal hearts in diabetic pregnancies by using Doppler echocardiography.

METHODS: This prospective study included 119 pregnant women divided into three groups. Group 1 included 47 pregnant patients with pre-existing diabetes mellitus (DM), group 2 included 40 patients with gestational diabetes and group 3 included 32 non-diabetic pregnant women. M-mode echocardiography was used to measure the thickness of the fetal ventricular walls and interventricular septum. The mitral and tricuspid early (E) and late (A) diastolic velocities and the ventricular shortening fraction were measured.

RESULTS: HbA1c % was significantly lower in gestational diabetes group compared with the pre-existing diabetes group. The interventricular septum was significantly thicker in the pre-existing diabetes group compared with other groups. Tricuspid and mitral E/A ratios were significantly lower in the pre-existing diabetes group compared with gestational diabetes and control groups. Moreover, there were no significant differences in the tricuspid and mitral E/A ratios between gestational diabetes group and the control group. The right and left ventricular shortening fractions were similar in the three groups.

CONCLUSION: Fetuses of women with well-controlled gestational diabetes lack the diastolic dysfunction that is present in fetuses of women with pre-existing diabetes.

Fouda, M. A., R. M. Allam, F. M. Moftah, and R. A. M. El-Fetouh, "The Role of ID-NAT in Enhancing Blood Safety at the Egyptian National Cancer Institute - A 5 Year Experience", Journal of the Egyptian Society of Haematology & Research, vol. 14, issue 2, pp. 1-6, 2018.
Fouda, K. Z., "Effect of Low Energy versus Medium Energy Radial Shock Wave Therapy in The Treatment of Chronic Planter Fasciitis", International Journal of Physiotherapy , vol. 3, issue 1, pp. 5-10, 2016. final_article_2016.pdf
Fouda, M. E., and A. G. Radwan, "Fractional-order memristor response under dc and periodic signals", Circuits, Systems, and Signal Processing, vol. 34, no. 3: Springer US, pp. 961–970, 2015. Abstract
n/a
Fouda, M. E., A. S. Elwakil, and A. Allagui, "Commercial supercapacitor parameter estimation from step voltage excitation", International Journal of Circuit Theory and Applications, vol. 47, no. 10, pp. 1705–1712, 2019. Abstract
n/a
Fouda, M. E., A. G. Radwan, and A. Elwakil, "Memristor and Inverse Memristor: Modeling, Implementation and Experiments", Advances in Memristors, Memristive Devices and Systems: Springer International Publishing, pp. 371–392, 2017. Abstract
n/a
Fouda, M. E., A. G. Radwan, and A. S. Elwakil, "Series and parallel circuit models containing memristors and inverse memristors", Electronics, Circuits, and Systems (ICECS), 2015 IEEE International Conference on: IEEE, pp. 292–295, 2015. Abstract
n/a
Fouda, A. Y., A. S. Newsome, S. Spellicy, J. L. Waller, W. Zhi, D. C. Hess, A. Ergul, D. J. Edwards, S. C. Fagan, and J. A. Switzer, "Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial.", Stroke, vol. 48, issue 10, pp. 2885-2887, 2017 10. Abstract

BACKGROUND AND PURPOSE: Minocycline is under investigation as a neurovascular protective agent for stroke. This study evaluated the pharmacokinetic, anti-inflammatory, and safety profile of minocycline after intracerebral hemorrhage.

METHODS: This study was a single-site, randomized controlled trial of minocycline conducted from 2013 to 2016. Adults ≥18 years with primary intracerebral hemorrhage who could have study drug administered within 24 hours of onset were included. Patients received 400 mg of intravenous minocycline, followed by 400 mg minocycline oral daily for 4 days. Serum concentrations of minocycline after the last oral dose and biomarkers were sampled to determine the peak concentration, half-life, and anti-inflammatory profile.

RESULTS: A total of 16 consecutive eligible patients were enrolled, with 8 randomized to minocycline. Although the literature supports a time to peak concentration (T) of 1 hour for oral minocycline, the T was estimated to be at least 6 hours in this cohort. The elimination half-life (available on 7 patients) was 17.5 hours (SD±3.5). No differences were observed in inflammatory biomarkers, hematoma volume, or perihematomal edema. Concentrations remained at neuroprotective levels (>3 mg/L) throughout the dosing interval in 5 of 7 patients.

CONCLUSIONS: In intracerebral hemorrhage, a 400 mg dose of minocycline was safe and achieved neuroprotective serum concentrations. However, oral administration led to delayed absorption in these critically ill patients and should not be used when rapid, high concentrations are desired. Given the safety and pharmacokinetic profile of minocycline in intracerebral hemorrhage and promising data in the treatment of ischemic stroke, intravenous minocycline is an excellent candidate for a prehospital treatment trial.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01805895.

Fouda, R., H. Ammar, E. Sobhy, and A. M. Amin, "Unusual cause of pericardial effusion.", BMJ case reports, vol. 2012, 2012. Abstract

A 65-year-old Egyptian lady suffering from non-alcoholic liver cirrhosis was referred to our unit for evaluation of a massive pericardial effusion. Few weeks before presentation, she suffered from progressive abdominal distention and dyspnoea. She denied fever, rigors or other cardiorespiratory symptoms. Examination revealed shrunken liver, spleenomegaly and ascites. Chest was clear to auscultation and heart sounds were distant. Chest radiograph showed cardiomegaly and clear lung fields. Abdominal ultrasound confirmed the results of abdominal examination. Transthoracic echocardiogram (TTE) revealed a massive pericardial effusion (PEF) and rheumatic mitral stenosis. Chest tomography showed PEF and clear lung fields. One litre of exudate was removed via TTE-guided needle pericardiocentesis. A pericardio-peritoneal shunt was suspected, which was confirmed via a radioisotopic study. This case is among very few cases that reported PEF in a cirrhotic ascetic patient secondary to a radio-isotopically confirmed pericardio-peritoneal shunt in the literature.

Fouda M.S., Hendawey M.H., Hegazi G.A., Sharada H.M., El-Arabi Nagwa I., A. M.E., and S. E. R. and S, "Nanoparticles induce genetic, biochemical, and ultrastructure variations in Salvadora persica callus", Journal of Genetic Engineering and Biotechnology , vol. 19, issue 27, 2021.
Foudah, A. I., A. Alam, G. A. Soliman, M. A. Salkini, E. I. O. Ahmed, and H. S. Yusufoglu, "Pharmacognostical, Antioxidant and Antimicrobial studies of aerial part of Pulicaria crispa (Family: Asteraceae)", Bull. Env. Pharmacol. Life Sci, vol. 4, pp. 19–27, 2015. Abstract

The study was designed to investigate the active phytochemicals present in the methanolic extract (ME) of Pulicaria crispa (P. crispa). The antimicrobial and antioxidant activities were also explored. These investigations were carried with an aim to use this plant in future. The morphological, microscopical and physicochemical investigation was carried out before the investigation of phytochemicals for authentication purpose. The antimicrobial activity was tested against Gram-positive, Gram-negative bacteria, Aspergillus niger and Candida albicans. Ampicillin was used as a standard for comparing the zone of inhibition. The in vitro 2,2-Diphenyl-1-picrylhydrazyl (DPPH) and Ferric reducing ability (FRAP) models were used for the investigation of antioxidant activity. The results of the authenticated plant, phytochemical examination was shown the presence of biological active compounds. Marked antimicrobial and antioxidant activities were observed which may be due to the presence of tannins, phenols and flavonoids in the ME. The outcome of the present finding was suggested that it may be a good source of active antibacterial and antioxidant phytochemicals.

FOULADI, N. A. S. H. T. A. A. A., D. C. Wathes, and W. F. Marei, "EMBRYOLOGY: DIVERSE EFFECTS OF POLYUNSATURATED FATTY ACIDS ON OOCYTE MATURATION AND DEVELOPMENT IN VITRO", INTERNATIONAL JOURNAL OF FERTILITY AND STERILITY, vol. 5, issue 1, pp. 31-32, 2011. Abstract
n/a
FOULADI, N. A. S. H. T. A. A. A., D. C. Wathes, and W. F. Marei, "EMBRYOLOGY: DIVERSE EFFECTS OF POLYUNSATURATED FATTY ACIDS ON OOCYTE MATURATION AND DEVELOPMENT IN VITRO", INTERNATIONAL JOURNAL OF FERTILITY AND STERILITY, vol. 5, no. 1, pp. 31–32, 2011. Abstract
n/a
Fouladi-Nashta, A. A., F. Ghafari, and W. F. Marei, "Role of hyaluronic acid in maturation and further early embryo development of bovine oocytes", REPRODUCTION IN DOMESTIC ANIMALS, vol. 47: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, pp. 454-454, 2012. Abstract
n/a
Fouladi-Nashta, A. A., W. Marei, and D. C. Wathes, "Diverse effects of polyunsaturated fatty acids on oocyte maturation and development in vitro", REPRODUCTION IN DOMESTIC ANIMALS, vol. 44: WILEY-BLACKWELL PUBLISHING, INC COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA, pp. 71–71, 2009. Abstract
n/a
Fouladi-Nashta, A. A., K. A. Raheem, W. F. Marei, F. Ghafari, and G. M. Hartshorne, "Regulation and roles of the hyaluronan system in mammalian reproduction", Reproduction, 2016/11/02, vol. 153, no. 2, pp. R43-R58, Feb, 2017. AbstractWebsite

Hyaluronan (HA) is a non-sulphated glycosaminoglycan polymer naturally occurring in many tissues and fluids of mammals, including the reproductive system. Its biosynthesis by HA synthase (HAS1-3) and catabolism by hyaluronidases (HYALs) are affected by ovarian steroid hormones. Depending upon its molecular size, HA functions both as a structural component of tissues in the form of high-molecular-weight HA or as a signalling molecule in the form of small HA molecules or HA fragments with effects mediated through interaction with its specific cell-membrane receptors. HA is produced by oocytes and embryos and in various segments of the reproductive system. This review provides information about the expression and function of members of the HA system, including HAS, HYALs and HA receptors. We examine their role in various processes from folliculogenesis through oocyte maturation, fertilisation and early embryo development, to pregnancy and cervical dilation, as well as its application in assisted reproduction technologies. Particular emphasis has been placed upon the role of the HA system in pre-implantation embryo development and embryo implantation, for which we propose a hypothetical sequential model.

Fouladi-Nashta, A. A., W. F. Marei, and F. Ghafari, "Small Size Hyluronan Promotes Bovine Oocyte Maturation and Embryo Development In Vitro.", BIOLOGY OF REPRODUCTION: SOC STUDY REPRODUCTION 1603 MONROE ST, MADISON, WI 53711-2021 USA, pp. 105-105, 2010. Abstract
n/a
Fouladi-Nashta, A., W. F. Marei, D. Schust, J. Sugimoto, T. Oda, Y. Jinno, Y. Hayashi, E. Mizutani, T. Kitaori, and K. Katano, "Session 67: Scientific challenges in early pregnancy achievement", Human Reproduction, vol. 28, issue suppl 1: ESHRE, pp. i106-i108, 2013. Abstract
n/a
Fouladi-Nashta, A. A., K. A. Raheem, W. F. Marei, F. Ghafari, and G. M. Hartshorne, "Regulation and roles of the hyaluronan system in mammalian reproduction", Reproduction, vol. 153, no. 2, pp. R43-R58, Feb, 2017. AbstractWebsite

Hyaluronan (HA) is a non-sulphated glycosaminoglycan polymer naturally occurring in many tissues and fluids of mammals, including the reproductive system. Its biosynthesis by HA synthase (HAS1-3) and catabolism by hyaluronidases (HYALs) are affected by ovarian steroid hormones. Depending upon its molecular size, HA functions both as a structural component of tissues in the form of high-molecular-weight HA or as a signalling molecule in the form of small HA molecules or HA fragments with effects mediated through interaction with its specific cell-membrane receptors. HA is produced by oocytes and embryos and in various segments of the reproductive system. This review provides information about the expression and function of members of the HA system, including HAS, HYALs and HA receptors. We examine their role in various processes from folliculogenesis through oocyte maturation, fertilisation and early embryo development, to pregnancy and cervical dilation, as well as its application in assisted reproduction technologies. Particular emphasis has been placed upon the role of the HA system in pre-implantation embryo development and embryo implantation, for which we propose a hypothetical sequential model.

Fouladi-Nashta, A., and W. F. Marei, "Is hyaluronan essential for embryo implantation? Lesson from studies in sheep", HUMAN REPRODUCTION, vol. 28: OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, pp. 106-106, 2013. Abstract
n/a
Fouladi-Nashta, A. A., W. Marei, and D. C. Wathes, "Diverse effects of polyunsaturated fatty acids on oocyte maturation and development in vitro", REPRODUCTION IN DOMESTIC ANIMALS, vol. 44: WILEY-BLACKWELL PUBLISHING, INC COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA, pp. 71-71, 2009. Abstract
n/a
Fouly Mostafa, M., M. M. Aboudina, and F. A. Hussien, "Novel buck converter architectures for large step-down conversion ratio", Circuits and Systems (MWSCAS), 2014 IEEE 57th International Midwest Symposium on: IEEE, pp. 773–776, 2014. Abstract
n/a